Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

MelmarT Melanoma Margins Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma (MelmarT)

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2016 by Australia and New Zealand Melanoma Trials Group
Peter MacCallum Cancer Centre, Australia
Norfolk and Norwich University Hospitals NHS Foundation Trust
Information provided by (Responsible Party):
Australia and New Zealand Melanoma Trials Group Identifier:
First received: June 13, 2014
Last updated: July 14, 2016
Last verified: July 2016
Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with a primary invasive cutaneous melanomas >=1mm thick to determine differences in the rate of local recurrence and melanoma specific survival. A reduction in margins is expected to improve quality of life in patients

Condition Intervention Phase
Cutaneous Melanoma by AJCC V7 Stage
Procedure: Wide Local Excision = 1cm Margin
Procedure: Wide Local Excision = 2cm Margin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase III, Multi-centre, Multi-national Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma

Resource links provided by NLM:

Further study details as provided by Australia and New Zealand Melanoma Trials Group:

Primary Outcome Measures:
  • Local Melanoma Recurrence (Melanoma Specific Survival) [ Time Frame: 0-120 months ]
    Time from randomisation to clinically, histologically or radiologically confirmed local recurrence of melanoma including satellite lesions and in transit metastases to regional draining lymph nodes.

Secondary Outcome Measures:
  • Recurrence-Free Survival [ Time Frame: 0-120 months ]
    Time from randomisation to any clinical, histological or radiologically confirmed melanoma recurrence or death from any cause.

  • QoL and neuropathic pain assessments Neuropathic Pain (PainDetect) [ Time Frame: Baseline, 3, 6 12, 24 & 60 months. ]
    Quality of Life

  • Overall Survival [ Time Frame: 0-120 Months ]
    Time from randomisation to death from any cause.

  • Adverse events [ Time Frame: Within 1 year ]

    An Adverse Event (AE) is any untoward medical occurrence in a participant administered a treatment which does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavourable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the treatment timing, whether or not considered related to the treatment. An AE is any adverse change (developing or worsening) from the participant's pre-treatment condition, including intercurrent illness.

    AEs and any pre-existing medical conditions will be recorded at the Baseline assessment and routinely at Follow Up, until the participant completes the study, withdraws or dies.

  • Surgery related adverse events [ Time Frame: Up to 30 days from randomisation ]

    The following surgical adverse events will be recorded from the time of trial treatment to 30 days following the wide excision (inclusive):

    • wound separation
    • seroma/haematoma at wide local excision site
    • haemorrhage
    • infection
    • skin graft failure
    • necrosis of flap used for reconstruction
    • deep venous thrombosis
    • urinary tract infection
    • pneumonia
    • cardiac complications

  • Health System Resource Use [ Time Frame: Baseline, 3, 6, 12, 24 and 60 months ]
    All hospitalisations and other interventions will be captured in order to measure resource use.

Estimated Enrollment: 400
Study Start Date: December 2014
Estimated Study Completion Date: December 2029
Estimated Primary Completion Date: December 2029 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm A Wide Local Excision = 1cm Margin

ARM A: Experimental Arm Wide Local Excision = 1cm Margin + Sentinel Lymph Node Biopsy

+/- Reconstruction

Procedure: Wide Local Excision = 1cm Margin
A wide local excision involves removing an extra "safety margin" of healthy skin surrounding the original melanoma site to ensure that any remaining scattered melanoma tumour cells are removed that may have been left behind after the first initial biopsy/surgery.
Active Comparator: Arm B Wide Local Excision = 2cm Margin

ARM B:Control Arm Wide Local Excision = 2cm Margin + Sentinel Lymph Node Biopsy

+/- Reconstruction

Procedure: Wide Local Excision = 2cm Margin
A wide local excision involves removing an extra "safety margin" of healthy skin surrounding the original melanoma site to ensure that any remaining scattered melanoma tumour cells are removed that may have been left behind after the first initial biopsy/surgery.

Detailed Description:
This study will determine whether there is a difference in local recurrence rates and melanoma survival rates for patients treated with either a 1cm excision margin or 2cm margin for both intermediate & high risk melanomas. The study is designed to be able to prove or disprove that there is no difference in risk of the tumour recurring around the scar or anywhere else in the body between the two groups of patients. This study is designed to show that the risk of long-term pain associated with surgery can be halved. If the study shows no risk of the tumour recurrence then we will also be able to determine how much of an impact the narrower excision has on patients in terms of improved quality of life and reduced side effects from the surgery and melanoma disease. This trial will also evaluate and determine the economic impact of narrower excision margins on the health services and society in general.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients must have a primary invasive cutaneous melanoma of Breslow thickness greater than 1 millimetre as determined by diagnostic biopsy (narrow excision, incision or punch biopsy) and subsequent histopathological analysis.
  2. Patients must have had the invasive primary completely excised, including any in situ component but excluding melanocytic atypia, with a narrow margin, either in one stage or more than one stage in the case where an incision or punch biopsy has previously been performed. This information, including measured margins of lateral and deep clearance must be documented on the pathology report.
  3. Must have a primary melanoma that is cutaneous (including head, neck, trunk, extremity, scalp, palm, sole).
  4. An uninterrupted 2cm margin must be technically feasible around biopsy scar or primary melanoma.
  5. Randomisation and the primary study intervention, including staging sentinel node biopsy, must be completed by 120 days of original diagnosis.
  6. Patients must be 18 years or older at time of consent.
  7. Patient must be able to give informed consent and comply with the treatment protocol and follow-up plan.
  8. Life expectancy of at least 10 years from the time of diagnosis, not considering the melanoma in question, as determined by the PI.
  9. Patients must have an ECOG performance score between 0 and 1.
  10. A survivor of prior cancer is eligible provided that ALL of the following criteria are met and documented:

    • The patient has undergone potentially curative therapy for all prior malignancies,
    • There has been no evidence of recurrence of any prior malignancies for at least FIVE years (except for successfully treated cervical or non-melanoma skin cancer with no evidence of recurrence), and
    • The patient is deemed by their treating physician to be at low risk of recurrence from previous malignancies.

Exclusion Criteria:

  1. Uncertain diagnosis of melanoma i.e. so-called 'melanocytic lesion of unknown malignant potential'.
  2. Patient has already undergone wide local excision at the site of the primary index lesion.
  3. Patient unable or ineligible to undergo staging sentinel lymph node biopsy of the primary index lesion.
  4. Desmoplastic or neurotropic melanoma.
  5. Microsatellitosis as per AJCC 2009 definition
  6. Subungual melanoma
  7. Patient has already undergone a local flap reconstruction of the defect after excision of the primary and determination of an accurate excision margin is impossible.
  8. History of previous or concurrent (i.e., second primary) invasive melanoma.
  9. Melanoma located distal to the metacarpophalangeal joint, on the tip of the nose, the eyelids or on the ear, mucous membranes or internal viscera.
  10. Physical, clinical, radiographic or pathologic evidence of satellite, in-transit, regional, or distant metastatic melanoma.
  11. Patient has undergone surgery on a separate occasion to clear the lymph nodes of the probable draining lymphatic field, including sentinel lymph node biopsy, of the index melanoma.
  12. Any additional solid tumour or hematologic malignancy during the past 5 years except T1 skin lesions of squamous cell carcinoma, basal cell carcinoma, or uterine/cervical cancer.
  13. Melanoma-related operative procedures not corresponding to criteria described in the protocol.
  14. Planned adjuvant radiotherapy to the primary melanoma site after Wide Local Excision is not permitted as part of the protocol and any patients given this treatment would be excluded from the study.
  15. History of organ transplantation.
  16. Oral or parenteral immunosuppressive agents (not topical or inhaled steroids) at any time during study participation or within 6 months prior to enrolment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02385214

Contact: ANZMTG Coordinator 61 2 9911 7200

Australia, New South Wales
Melanoma Institute Australia - Poche Centre Recruiting
North Sydney, New South Wales, Australia, 2060
Contact: Andrew Spillane    612 9911 7200   
Contact: ANZMTG Coordinator    612 9911 7200   
Principal Investigator: Andrew Spillane         
Australia, Queensland
Gold Coast Melanom Clinic Recruiting
Coolangatta, Queensland, Australia, 4225
Contact: Heidi Smith    +61 7 5536 8855   
Principal Investigator: Nic Crampton         
Australia, Victoria
Peter MacCallum Cancer Centre Division of Cancer Surgery Recruiting
Melbourne, Victoria, Australia, 3002
Contact: Michael Henderson    613 9656 3527   
Contact: ANZMTG Coordinator    612 9911 7200   
Principal Investigator: Michael Henderson         
Sub-Investigator: David Gyorki         
Alfred Hospital Recruiting
Melbourne, Victoria, Australia, 3004
Contact: Marisa Ciskos    +61 3 9076 0365   
Contact: Rachel         
Principal Investigator: Victoria Mar         
Principal Investigator: Michael Leung         
United Kingdom
Hull and East Yorkshire Hospitals NHS Trust Recruiting
East Yorkshire, England, United Kingdom, HU16 5JQ
Contact: Paula O'Reilly    (01482) 461250   
Contact: Karen Shepherd    (01482) 461250   
Principal Investigator: Paolo Matteucci         
Guy's and St Thomas' Hospital NHS Trust Recruiting
London, England, United Kingdom, SE1 7EH
Contact: Jenny Geh   
Principal Investigator: Jenny Geh         
The Christie NHS Foundation Trust Recruiting
Manchester, England, United Kingdom, M20 4BX
Contact: Pamela Hewitt    44 (0)161 446 8334   
Principal Investigator: Deemesh Oudit         
St Helens & Knowsley NHS Trust Recruiting
Prescott, Mersyside, United Kingdom, L35 5DR
Contact: Nicola Hornby    01744 646581   
Contact: Rachel Cassidy    01744 646581   
Principal Investigator: Mr Rowan Pritchard-Jones         
Oxford University Hospitals NHS Trust Recruiting
Headington, Oxford, United Kingdom, OX3 7LE
Contact: David Mukkath   
Principal Investigator: Oliver Cassell         
North Bristol NHS Trust Recruiting
Bristol, United Kingdom, BS10 5NB
Contact: Louise Solomon    0117 414 8118   
Principal Investigator: Ewan Wilson         
Mid Essex Hospital Services NHS Trust Recruiting
Essex, United Kingdom, CM1 7ET
Contact: Fiona McNeela   
Principal Investigator: Peter Dziewulski         
Royal Devon and Exeter NHS Foundation Trust Recruiting
Exeter, United Kingdom, EX2 5DW
Contact: John Anderson   
St. James University Hospital Recruiting
Leeds, United Kingdom, LS9 7TF
Contact: Emma Yates   
Principal Investigator: Howard Peach         
Royal Free London NHS Foundation Trust Recruiting
London, United Kingdom, NW3 2QG
Contact: Dominic Baxter   
Principal Investigator: Steven Hamilton         
Norfolk and Norwich University Hospital Recruiting
Norwich, United Kingdom, NR4 7UY
Contact: Sharon Walton    01603 288128   
Contact: Beverly Underwood    01603 288128   
Principal Investigator: Mar Moncrieff         
Sponsors and Collaborators
Australia and New Zealand Melanoma Trials Group
Peter MacCallum Cancer Centre, Australia
Norfolk and Norwich University Hospitals NHS Foundation Trust
Principal Investigator: Marc Moncrieff Norfolk & Norwich University Hospital
Principal Investigator: Michael Henderson Peter MacCallum Cancer Center
  More Information

Additional Information:
Responsible Party: Australia and New Zealand Melanoma Trials Group Identifier: NCT02385214     History of Changes
Obsolete Identifiers: NCT01457157
Other Study ID Numbers: ANZMTG 03.12
Study First Received: June 13, 2014
Last Updated: July 14, 2016

Keywords provided by Australia and New Zealand Melanoma Trials Group:

Additional relevant MeSH terms:
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas processed this record on May 22, 2017